NO20082387L - Kompetitive domene-antistofformater som binder interleukin 1 reseptor type 1 - Google Patents

Kompetitive domene-antistofformater som binder interleukin 1 reseptor type 1

Info

Publication number
NO20082387L
NO20082387L NO20082387A NO20082387A NO20082387L NO 20082387 L NO20082387 L NO 20082387L NO 20082387 A NO20082387 A NO 20082387A NO 20082387 A NO20082387 A NO 20082387A NO 20082387 L NO20082387 L NO 20082387L
Authority
NO
Norway
Prior art keywords
dab
domain antibody
receptor type
antibody formats
relates
Prior art date
Application number
NO20082387A
Other languages
English (en)
Norwegian (no)
Inventor
Ian M Tomlinson
Philip D Drew
Amrik Basran
Rudolf M T De Wildt
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20082387L publication Critical patent/NO20082387L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
NO20082387A 2005-12-01 2008-05-26 Kompetitive domene-antistofformater som binder interleukin 1 reseptor type 1 NO20082387L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74221805P 2005-12-01 2005-12-01
PCT/GB2006/004474 WO2007063311A2 (en) 2005-12-01 2006-11-30 Competitive domain antibody formats that bind interleukin 1 receptor type 1

Publications (1)

Publication Number Publication Date
NO20082387L true NO20082387L (no) 2008-07-31

Family

ID=37814249

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082387A NO20082387L (no) 2005-12-01 2008-05-26 Kompetitive domene-antistofformater som binder interleukin 1 reseptor type 1

Country Status (14)

Country Link
US (1) US20080311111A1 (enExample)
EP (1) EP1957537A2 (enExample)
JP (1) JP2009517069A (enExample)
KR (1) KR20080077237A (enExample)
CN (1) CN101466734A (enExample)
AU (1) AU2006321367B2 (enExample)
BR (1) BRPI0619224A2 (enExample)
CA (1) CA2629850A1 (enExample)
CR (1) CR10025A (enExample)
EA (1) EA200801166A1 (enExample)
MA (1) MA30019B1 (enExample)
NO (1) NO20082387L (enExample)
TW (1) TW200736276A (enExample)
WO (1) WO2007063311A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2068889T3 (da) 2006-08-10 2020-02-03 Roy C Levitt Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
MX2009013137A (es) * 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA201000785A1 (ru) * 2007-12-13 2011-02-28 Глаксо Груп Лимитед Композиции для доставки в легкие
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
US9181327B2 (en) 2008-01-07 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-HIV domain antibodies and method of making and using same
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
US9243061B2 (en) * 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
EA201270174A1 (ru) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
WO2012053828A2 (ko) * 2010-10-20 2012-04-26 주식회사 한독약품 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
JP2014501515A (ja) * 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
EP3363812A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
JP6258199B2 (ja) 2011-06-23 2018-01-10 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
KR101592871B1 (ko) * 2013-03-19 2016-02-11 부산대학교 산학협력단 Akt에 의해 활성화되는 글리코겐 합성효소 키나아제 베타 억제용 펩타이드
ES2900852T3 (es) 2014-05-16 2022-03-18 Ablynx Nv Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
NO2768984T3 (enExample) 2015-11-12 2018-06-09
AU2016351710B2 (en) 2015-11-13 2023-08-03 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
IL263704B2 (en) 2016-06-23 2024-09-01 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
KR20230073346A (ko) 2016-11-28 2023-05-25 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
CN110191896B (zh) 2017-01-17 2023-09-29 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
KR102653724B1 (ko) 2017-01-17 2024-04-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
SG11201908154RA (en) 2017-03-31 2019-10-30 Ablynx Nv Improved immunogenicity assays
EP3719035A4 (en) 2017-11-28 2021-09-01 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE INCLUDING AN ANTIGEN BINDING DOMAIN AND A TRANSPORT SECTION
EP3802831A4 (en) * 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
CN110361310A (zh) * 2019-06-18 2019-10-22 东南大学 一种房间换气次数的cadr测量方法
JP2023526477A (ja) * 2020-05-20 2023-06-21 アンスティテュ・クリー 合成単一ドメインライブラリー

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
USRE35450E (en) * 1987-11-25 1997-02-11 Immunex Corporation Soluble human interleukin-1 receptors, compositions and method of use
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US20040101528A1 (en) * 1988-02-25 2004-05-27 Dower Steven K. Type I IL-1 receptors
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US6090775A (en) * 1991-10-31 2000-07-18 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
US5391071A (en) * 1993-10-29 1995-02-21 Eastman Kodak Company Apparatus and method for inspecting and cleaning lips of castings die
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
ES2312179T3 (es) * 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6326472B1 (en) * 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6419944B2 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6423321B2 (en) * 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
CA2464529A1 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Method of treating estrogen responsive breast cancer
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
SG2013096847A1 (en) * 2002-09-06 2017-05-30 Medarex Llc Therapeutic human anti-il-1r1 monoclonal antibody
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20090191217A1 (en) * 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
US7103259B1 (en) * 2005-03-21 2006-09-05 Hannstar Display Corporation Structure for affixing an optical plate on a frame in a panel display

Also Published As

Publication number Publication date
EP1957537A2 (en) 2008-08-20
CN101466734A (zh) 2009-06-24
BRPI0619224A2 (pt) 2017-06-20
AU2006321367A1 (en) 2007-06-07
WO2007063311A2 (en) 2007-06-07
CR10025A (es) 2008-09-22
US20080311111A1 (en) 2008-12-18
JP2009517069A (ja) 2009-04-30
MA30019B1 (fr) 2008-12-01
TW200736276A (en) 2007-10-01
KR20080077237A (ko) 2008-08-21
AU2006321367B2 (en) 2011-11-03
EA200801166A1 (ru) 2008-12-30
CA2629850A1 (en) 2007-06-07
WO2007063311A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20082387L (no) Kompetitive domene-antistofformater som binder interleukin 1 reseptor type 1
NO20082215L (no) Ikke-kompetitive domene-antistofformater som binder interleukin 1 reseptortype 1
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
EA200800696A1 (ru) Полипептиды и антитела
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
WO2006038027A3 (en) SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR
AU2020224154A8 (en) Multifunctional molecules that bind to calreticulin and uses thereof
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
WO2005016266A3 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
HK1200464A1 (en) Immunobinders directed against tnf
NL300919I2 (nl) Brodalumab
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
AU2008338591A8 (en) Binding molecules to the human OX40 receptor
WO2005103081A3 (en) Human monoclonal antibodies against cd20
CA3030662A1 (en) New indications for anti-il-1-beta therapy
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2003035839A3 (en) Target specific screening andits use for identifying target binders
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2008013948A3 (en) Tyrosine phosphorylation sites
WO2011112566A3 (en) Basigin binding proteins
CN115715325A (zh) 结合bcma的单可变结构域及抗原结合分子
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2007075915A3 (en) Monoclonal antibodies against orthopoxviruses